SCHEMBL3246010

SCHEMBL3246010

CCCOC(=O)c1c[nH]c2c(=O)[nH]c3ccc(S(=O)(=O)N(CCO)C(C)C)cc3c12

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.40
HSD17B10 Q99714 5/20 0.40
ALDH1A1 P00352 6/20 0.37
USP2 O75604 2/20 0.37
HPGD P15428 2/20 0.37
MAPT P10636 3/20 0.36
GABRA1 P14867 1/20 0.36
GABRB1 P18505 1/20 0.36
GABRA3 P34903 1/20 0.36
GABRB2 P47870 1/20 0.36
ESR1 P03372 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
GAA P10253 1/20 0.35
TSHR P16473 2/20 0.35
LMNA P02545 1/20 0.34
MAPK1 P28482 1/20 0.34
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3249689 0.91 KDM4E (0.42) KDM4EHSD17B10ALDH1A1USP2HPGD
SCHEMBL3249686 0.87 KDM4E (0.35) KDM4EHSD17B10ALDH1A1USP2HPGD
SCHEMBL3255607 0.87 KDM4E (0.40) KDM4EHSD17B10ALDH1A1USP2HPGD
SCHEMBL3251345 0.86 KDM4E (0.38) KDM4EHSD17B10ALDH1A1USP2HPGD
SCHEMBL3245537 0.85 KDM4E (0.41) KDM4EHSD17B10ALDH1A1USP2HPGD
SCHEMBL3256111 0.85 KDM4E (0.35) KDM4EHSD17B10ALDH1A1GABRA1GABRB1
SCHEMBL3255500 0.84 KDM4E (0.40) KDM4EHSD17B10ALDH1A1USP2HPGD
SCHEMBL13928176 0.84 MAPT (0.34) KDM4EHSD17B10ALDH1A1USP2HPGD
SCHEMBL3249572 0.83 KDM4E (0.41) KDM4EHSD17B10ALDH1A1USP2HPGD
SCHEMBL13950919 0.83 KDM4E (0.39) KDM4EHSD17B10ALDH1A1USP2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 KDM4E 1970/4885HSD17B10 3847/4885ALDH1A1 3830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.